Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 24, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 24, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/24/14 - "Methods of Administering Drugs in an Implantable Multi-Chamber Pump" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Gibson, Susan P.; Vanhove, Geertrui F., filed on March 27, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Jazz Pharmaceuticals,
10/24/14 - 'Unsung' cells double the benefits of a new osteoporosis drug
By a News Reporter-Staff News Editor at Health& Medicine Week Experiments in mice with a bone disorder similar to that in women after menopause show that a scientifically overlooked group of cells are likely crucial to the process of bone loss caused by the disorder, according to Johns Hopkins researchers. A summary of their work will be publishe
10/24/14 - AbbVie's HUMIRA adalimumab Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and...
AbbVie's HUMIRA adalimumab Receives U.S. By a News Reporter-Staff News Editor at Health& Medicine Week AbbVie announced that the U.S. Food and Drug Administration has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis to reducing signs and symptoms in patients ages 2 an
10/24/14 - Actavis to Acquire Durata Therapeutics, Inc.
By a News Reporter-Staff News Editor at Health& Medicine Week Actavis plc, a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc., an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, announced that they have
10/24/14 - Aphios Granted United States Patent for Nanotechnology Formulation of Poorly Soluble Drugs
By a News Reporter-Staff News Editor at Health& Medicine Week Aphios Corporation announced that it has been granted United States Patent No. 8,703,727 entitled "Nanotechnology Formulation of Poorly Soluble Compounds," for difficult to formulate and deliver drugs. These techniques can be applied to a number of existing drugs as well as to several
10/24/14 - China Pharmaceuticals and Healthcare Report Q4 2014 - New Report Available [ClickPress (UK)]
In this quarter, the country is ranked sixth, behind Hong Kong but in front of Singapore in the 19 key Asia Pacific markets. Full Report Details at- http://www.fastmr.com/prod/878947-china-pharmaceuticals-and-healthcare-report-q4. aspx? afid= 301 Key Trends And Developments* In August 2014, Shanghai Fosun Pharmaceutical Group, a leading healthcare.
10/24/14 - Chinese Patent Medicine Market Trends Analysis and 2018 Forecasts
ReportsnReports.com adds Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report to the pharmaceuticals category of its online industry research reports library. It analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine...
10/24/14 - Covidien Announces U.S. Food and Drug Administration 510k Clearance for Nellcor? Portable SpO2 Patient Monitoring System
By a News Reporter-Staff News Editor at Health& Medicine Week Covidien plc announced U.S. Food and Drug Administration 510 clearance for the Nellcor? Portable SpO2 Patient Monitoring System. Part of a comprehensive Covidien respiratory function monitoring portfolio, this convenient, handheld patient monitor is simple to use and ideal for fast,
10/24/14 - Cydex Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 24 Cydex Pharmaceuticals, Lenexa, Kansas, has been assigned a patent developed by six co-inventors for "formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use." The co-inventors are Karen T. Johnson, Lawrence, Kansas, Rebecca L. Wedel, Lawrence, Kansas, Stephen G. Machatha, Overland Park, Ka
10/24/14 - Icahn School of Medicine at Mount Sinai opens genomics research facility in Branford [New Haven Register, Conn.]
Oct. 24 BRANFORD Connecticut's reputation as a center for biomedical research received a boost Thursday with an announcement that the Icahn School of Medicine at Mount Sinai has opened a state-of-the-art genomics research facility on Commercial Street. "We are investing in industry leaders like the Icahn School of Medicine at Mount Sinai so th
10/24/14 - Market Report, "PaxVax - Product Pipeline Review - 2014", published [ClickPress (UK)]
Global Markets Direct's,' PaxVax- Product Pipeline Review- 2014', provides an overview of the PaxVax's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of PaxVax's, complete with comparative analysis at various stages, therapeutics assessment by drug targ
10/24/14 - Oklahoma Medical Research Foundation selected to receive Innovation Grant from EMD Serono
By a News Reporter-Staff News Editor at Health& Medicine Week An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono. "We have the capability of doing a lot of important science here with OMRF's Multiple Sc
10/24/14 - Pacira Pharmaceuticals Reports Data Supporting Safety of EXPAREL in Peripheral Nerve Block [Manufacturing Close - Up]
Pacira Pharmaceuticals reported data demonstrating that EXPAREL used in peripheral nerve blocks has comparable safety to placebo and bupivacaine HCl. According to a release from the Company, the analysis, based on a review of six Phase 1-3 clinical trials, will be presented during a podium session at the annual meeting of the American Society of...
10/24/14 - Research and Markets Adds Report: Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography)... [Manufacturing Close - Up]
Research and Markets has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market through 2020" report to its offerings. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to deve
10/24/14 - Veristat and Molecular Templates Sign Preferred Provider Pact for Refractory Non-Hodgkin's B-Cell Lymphoma Trial [Manufacturing Close - Up]
"We are elated following the FDA's approval of our IND application for MT-3724 and are eager to begin the next steps of our clinical journey with Veristat. Veristat will support the initiation of our Phase I program, which will assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of MT-3724 in patients with non-Hodgkin's B-Ce
10/24/14 - Wellness Uprising Offers Safe, Natural, Effective Solutions for Today's Health Concerns
Wellness Uprising is dedicated to the thesis that every living organism on this planet had the ability to enjoy perfect health- long before the big chemical and drug companies lobbied their way into the controls of the FDA and EPA. Pell believes that, contrary to drug company ads, using your body in the way it was designed is the best way to pay th
10/23/14 - 'Exceptional Leadership, 100 Percent Government Support Crucial to NAFDAC's Successes' [interview]
Abubakar Jimoh is the Director of Special Duties at the National Agency for Food Drug Administration and Control. Jimoh graduated from Kwara State School of Basic Studies in 1982 and from the university of Ibadan in 1987 with B.sc, 2nd class upper division in Political Science and was the best graduating student in the faculty of social sciences.
10/23/14 - Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that its collaboration partner, Celgene, and investigators on the sotatercept program will present preclinical and interim clinical data at the...
10/23/14 - Actavis Confirms Appeals Court Upholds Lo Loestrin Fe Patent
Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications for generic versions of Actavis' Lo Loestrin Fe.
10/23/14 - Actavis Says US Appeals Court Upholds Patent Of Lo Loestrin Fe
DUBLIN- Irish specialty pharmaceutical company Actavis plc Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling on its birth control pill Lo Loestrin Fe. Earlier in January, US District court of New Jersey has found United States Patent No. 7,704,984 to be valid and infringed by Lupin...
10/23/14 - Aduro Presents Updated Interim Results from Phase 1b Clinical Trial in Mesothelioma at International Mesothelioma Interest Group Conference
Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced the presentation of updated safety and efficacy data from an ongoing Phase 1 b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma. The results were presented by Raffit Hassan, M
10/23/14 - Alcobra Announces Presentation of New Data From Phase III Adult ADHD Study at AACAP Annual Meeting
Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder and Fragile X Syndrome, announced the presentation of new data from a Phase III study of Metadoxine Extended Release in adults with ADHD at the 61st annual mee
10/23/14 - Alimera Sciences to Release Third Quarter 2014 Results
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will release its third quarter of fiscal year 2014 financial results after the market close on Thursday, November 6, 2014. About Alimera Sciences, Inc. Alimera Sci
10/23/14 - American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety Risks
Cerus Corporation today announced that the American Red Cross will participate in Cerus clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption to regions in the United States with outbreaks of chikungunya and dengue virus. "In Puerto Rico, dengue viruses have been p
10/23/14 - Amgen: BiTE Immunotherapy Blinatumomab Secures FDA Priority Review Designation [Professional Services Close - Up]
Amgen reported that that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for the investigational bispecific T cell engager antibody construct, blinatumomab. Amgen said that a Marketing Authorization Application has also been submitted to the European Medicines Agency via the centralized procedure for.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415